Genentech

Roche's Tecentriq fails trial in form of urothelial cancer
Roche's Tecentriq fails trial in form of urothelial cancer
Reuters
Roche
Genentech
clinical trials
Tecentriq
urothelial cancer
bladder cancer
Flag link:
Who are the 10 Most Innovative Biopharma Companies?
Who are the 10 Most Innovative Biopharma Companies?
BioSpace
innovation
Regeneron
Verily
Illumina
Biogen
Bayer
Bluebird Bio
Novartis
GSK
Genentech
Amgen
Flag link:
Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials
Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials
BioSpace
Roche
Genentech
Arcus Biosciences
clinical trials
colorectal cancer
pancreatic cancer
AB928
Flag link:
Roche's flu med Xofluza drives drug resistance and may be a bad choice for kids, study says
Roche's flu med Xofluza drives drug resistance and may be a bad choice for kids, study says
Fierce Pharma
Roche
Genentech
Xofluza
pediatrics
Flag link:
Bay Area Life Sciences Professionals Weigh In on Their Ideal Employers
Bay Area Life Sciences Professionals Weigh In on Their Ideal Employers
BioSpace
San Francisco
Bay Area
Genentech
Gilead Sciences
Roche
Amgen
Flag link:
Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity
Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity
BioSpace
Genentech
Pfizer
Merck
Amgen
Novartis
Flag link:
After more than a year, Gilead finds new chief medical officer
After more than a year, Gilead finds new chief medical officer
Biopharma Dive
Gilead Sciences
Roche
Genentech
Flag link:
Roche AI Program Can Predict Progression of Diabetic Retinopathy
Roche AI Program Can Predict Progression of Diabetic Retinopathy
BioSpace
artificial intelligence
Roche
Genentech
diabetic retinopathy
deep learning
Flag link:
Can Synthetic Biology Make Insulin Faster, Better and Cheaper?
Can Synthetic Biology Make Insulin Faster, Better and Cheaper?
Forbes
diabetes
insulin
drug pricing
Genentech
gene editing
Flag link:
Genentech submits a plan to nearly double its South San Francisco footprint
Genentech submits a plan to nearly double its South San Francisco footprint
Endpoints
Genentech
San Francisco
Flag link:
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
Pharmaforum
Roche
Perjeta
Herceptin
Genentech
HER2-positive breast cancer
Flag link:
FDA approves Rituxan biosimilar
FDA approves Rituxan biosimilar
Beckers Hospital Review
Pfizer
biosimilars
FDA
Ruxience
cancer
autoimmune disease
Genentech
Flag link:
Roche's Genentech goes on deal spree, unveiling third deal on the same day
Roche's Genentech goes on deal spree, unveiling third deal on the same day
Endpoints
Roche
Genentech
Sosei Heptares
Skyhawk Therapeutics
Convelo Therapeutics
Flag link:
Clover Therapeutics Launches With Eye on Age-Related Ocular Diseases
Clover Therapeutics Launches With Eye on Age-Related Ocular Diseases
BioSpace
Clover Therapeutics
start-ups
eye health
Genentech
Ocular Disease
Flag link:
GSK hires Branson from Genentech to boost AI team
GSK hires Branson from Genentech to boost AI team
Fierce Biotech
GSK
AI
Kim Branson
Genentech
hirings
Flag link:
Adaptive Biotechnologies Files for $230 Million IPO
Adaptive Biotechnologies Files for $230 Million IPO
CP Wire
Adaptive Biotechnologies
IPOs
Genentech
Flag link:
Adaptive Biotechnologies Files for $230 Million IPO
Adaptive Biotechnologies
Genentech
IPOs
Flag link:
[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone

[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone

CP Wire
life sciences
Source Explorer
Gilead Sciences
Roche
Mylan
Biogen
Genentech
AstraZeneca
Flag link:
[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone

life sciences
Source Explorer
Gilead Sciences
Roche
Mylan
Biogen
Genentech
AstraZeneca
Flag link:
Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech
Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech
Endpoints
Parvus Therapeutics
Genentech
drug discovery
autoimmune disease
Flag link:

Pages